|Mr. Thomas Charles Reilly||Chief Financial Officer||856.49k||N/A||1972|
|Dr. Steven B. Ketchum Ph.D.||President of Research & Development and Chief Scientific Officer||991.19k||N/A||1965|
|Mr. Aaron D. Berg||Executive VP & President of U.S.||913.7k||N/A||1963|
|Mr. Patrick Holt||President, CEO & Director||N/A||N/A||N/A|
|Mr. Jordan Zwick||Senior VP of Corporate Business Development & Investor Relations||N/A||N/A||1987|
|Mr. Jonathan N. Provoost||Executive VP and Chief Legal & Compliance Officer||N/A||N/A||N/A|
|Ms. Donna Pasek||Senior Vice President of Human Resources||N/A||N/A||N/A|
|Mr. Laurent Abuaf||President of Europe & Senior VP||N/A||N/A||N/A|
|Dr. Nabil Abadir||Chief Medical Officer of Global Medical Affairs||N/A||N/A||N/A|
|Dr. David Keenan Ph.D.||Executive VP of Technical Operations & President of Europe||N/A||N/A||N/A|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.